https://www.selleckchem.com/pr....oducts/pf-06463922.h
ity. To critically assess the clinical utility of striational antibodies (StrAbs) within paraneoplastic and myasthenia gravis serological evaluations. All Mayo Clinic patients tested for StrAbs from January 1 2012-December 31 2018 utilizing Mayo's Unified Data Platform (UDP) were reviewed for neurological diagnosis and cancer. 38,502 unique paraneoplastic and 1,899 MG patients were tested. In paraneoplastic evaluations, the StrAbs positivity rate was higher in cancer vs without cancer (5% [321/6775] vs 4% [1154/31727]; p0.0001;
Like
Comment
Share
